China Universal Asset Management Co., Ltd. Eagle Pharmaceuticals, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$15.21 - $22.88 $2,464 - $3,706	162 Added 94.19%	334 $5,000
Q3 2023 Oct 30, 2023	BUY	$15.21 - $22.88 $2,464 - $3,706	162 Added 94.19%	334 $5,000
Q2 2023 May 21, 2024	SELL	$17.74 - $31.87 $88 - $159	-5 Reduced 2.82%	172 $3,000
Q2 2023 Jul 27, 2023	SELL	$17.74 - $31.87 $88 - $159	-5 Reduced 2.82%	172 $3,000
Q1 2023 May 21, 2024	BUY	$25.06 - $34.09 $1,127 - $1,534	45 Added 34.09%	177 $5,000
Q1 2023 Apr 27, 2023	BUY	$25.06 - $34.09 $1,127 - $1,534	45 Added 34.09%	177 $5,000
Q4 2022 May 21, 2024	BUY	$24.98 - $39.77 $3,297 - $5,249	132 New	132 $3,000
Q4 2022 Jan 31, 2023	BUY	$24.98 - $39.77 $199 - $318	8 Added 6.45%	132 $4,000
Q3 2022 Oct 21, 2022	BUY	$26.42 - $47.12 $3,276 - $5,842	124 New	124 $3,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account